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Eﬀ ect of expanded insecticide-treated bednet coverage on 
child survival in rural Kenya: a longitudinal study
Greg W Fegan, Abdisalan M Noor, Willis S Akhwale, Simon Cousens, Robert W Snow
Summary
Background The potential of insecticide-treated bednets (ITNs) to contribute to child survival has been well documented 
in randomised controlled trials. ITN coverage has increased rapidly in Kenya from 7% in 2004 to 67% in 2006. We 
aimed to assess the extent to which this investment has led to improvements in child survival. 
Methods A dynamic cohort of about 3500 children aged 1–59 months were enumerated three times at yearly intervals 
in 72 rural clusters located in four districts of Kenya. The eﬀ ect of ITN use on mortality was assessed with Poisson 
regression to take account of potential eﬀ ect-modifying and confounding covariates. 
Findings 100 children died over 2 years. Overall mortality rates were much the same in the ﬁ rst and second years of 
the study (14·5 per 1000 person-years in the ﬁ rst year and 15·4 per 1000 person-years in the second). After adjustment 
for age, time period, and a number of other possible confounding variables, ITN use was associated with a 44% 
reduction in mortality (mortality rate ratio 0·56, 95% CI 0·33–0·96; p=0·04). This level of protection corresponds to 
about seven deaths averted for every 1000 ITNs distributed. 
Interpretation A combined approach of social marketing followed by mass free distribution of ITNs translated into 
child survival eﬀ ects that are comparable with those seen in previous randomised controlled trials. 
Introduction 
The beneﬁ t of using insecticide-treated bednets (ITNs) in 
Africa has been shown through carefully controlled 
eﬃ  cacy trials, resulting in a pooled estimate of a 
20% reduction in all cause mortality in children aged 
under 5 years.1 However, when delivered outside 
experimental settings as part of national programmes, 
the impressive results obtained during eﬃ  cacy trials 
might be constrained by lower coverage, poor compliance, 
or diﬀ erentials in use by wealthier communities at lower 
risk of child mortality. The diﬀ erence between eﬃ  cacy 
and eﬀ ectiveness2 has implications for the 
cost-eﬀ ectiveness of ITN distribution in Africa.3 The 
eﬀ ect of ITNs on mortality when delivered under 
operational conditions has only been measured in The 
Gambia, as part of a national campaign,4 and in one 
district in Tanzania after the promotion of socially 
marketed ITNs.5,6 Here, we assess the eﬀ ect on child 
survival of a combined approach of social marketing and 
free distribution of ITNs in Kenya that resulted in a rapid 
increase in ITN use by children aged less than 5 years 
from 7% in 2004, to 23·5% in 2005, to 67% in 2006.7 
Methods
Participants and procedures
The establishment of prospective surveillance in a sample 
of rural communities in four sentinel districts (Bondo, 
Kwale, Makueni, and Kisii) has been described in detail 
elsewhere.7 In brief, all homesteads within 18 randomly 
selected communities in each district were mapped with 
GPS (Garmin etrex, Garmin [Europe] Ltd, Southampton, 
UK). Homesteads that agreed to participate were 
recruited into the homestead cohort and de-jure resident 
homestead members were enumerated, including details 
of date of birth and sex, and each homestead member 
issued a unique identiﬁ er. All children aged less than 
5 years, resident at a census in December, 2004, to 
January, 2005, were recruited into the cohort and were 
revisited in 2005–06 and 2006–07 to track the ownership 
and use of bednets. Free mass distribution of bednets 
occurred in Kisii and Bondo in July, 2006, integrated with 
a measles campaign, and in Kwale and Makueni in Sept, 
2006, as a stand-alone campaign. Children exited the 
cohort if at subsequent census rounds they had 
out-migrated, their parent or guardian refused continued 
participation, or they had reached their ﬁ fth birthday, or 
had died. Children who in-migrated or were born during 
the interval between census rounds were added to the 
cohort. New births that did not survive the interval 
between census rounds were also included in the cohort. 
In-migrants who out-migrated between the census 
rounds were not included in the cohort. 
At each cross-sectional survey, bednet use among 
surviving children was ascertained, including whether 
the child was reported as usually using a net, and if so, 
whether they used a net the previous night. For all those 
who were reported as usually using a net, whether this 
net had been treated with insecticide, and if so, whether 
it had been treated within 6 months, was also recorded. 
Deaths were investigated separately through interviews 
with bereaved relatives. During these interviews net use 
and net treatment before the terminal illness was 
ascertained in a manner similar to that for surviving 
children. Deaths that occurred after 28 days of life and 
before the ﬁ fth birthday were the focus of the present 
study, consistent with eﬃ  cacy trials done in the 1990s.1 
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Child years of exposure were calculated after 
subdividing the study period into four 6-month periods 
from baseline until the last enumeration, and a child was 
deemed to have used an ITN if the enumeration identiﬁ ed 
a child as usually using a net that had either been treated 
within the last 6 months or was a longlasting ITN. Since 
the re-enumeration rounds took place once a year, there 
were no data on whether the net was retreated at the 
midpoint of a year. Thus, an assumption was made that a 
net was continuously eﬀ ective, and thus the child exposed 
to the eﬀ ect of a net, if the net had been retreated in the 
two adjacent 6-month periods. Within a period where a 
child was indicated to have started to use an ITN, based 
on the date of net acquisition provided during interviews 
with mothers or guardians, the date of acquisition was 
used to deﬁ ne the months of use. For example, a child 
born before July 1, 2006, and who survived to the end of 
the study and began to use an eﬀ ective net in September, 
2006, contributed 3 months of non-net use to the period 
July–December, 2006, and 3 months of net use to the 
same period. The exposure time was calculated for each 
of the age categories a child passed through during each 
of the four periods. For children who out-migrated or 
were age-censored we assumed that their net status did 
not change between the last time they were enumerated 
and the date they exited the cohort. 
A number of covariates potentially related to mortality 
were recorded during the study: the child’s age and sex; 
their mother’s age and education; and indicators of 
homestead economic status. District-speciﬁ c wealth 
quintiles were created by use of principal components 
analysis,8 on the basis of the education level and 
occupation of the homestead head, housing 
characteristics (type of wall, roof, and ﬂ oor), source of 
drinking water; type of sanitation facility, homestead 
size, and number of people per sleeping room.7 Within 
each district, transport routes and topography, 
government, mission and private health services, and 
physical barriers to travel (hills, rivers, and protected 
areas) were all mapped with GPS and assembled in 
ARCGIS version 9.0. A travel time algorithm developed 
in C++ code was used to deﬁ ne speed diﬀ erentials along 
the various footpath and road surfaces to curative 
services to estimate each homestead’s physical access to 
treatment in minutes.9 Previous work has suggested 
indirect beneﬁ ts to non-users of bednets at the 
community level,10,11 and a community-level ITN density 
measure was constructed on the basis of the number of 
ITNs per head per cluster and classiﬁ ed in quartiles in 
the Poisson regression analysis.
The longitudinal surveys were approved by the KEMRI 
National Ethical Review Committee (KEMRI SSC 
numbers 906 and 1107).
Statistical analysis 
All statistical analyses were done with Stata version 9.2. 
Mortality rates were calculated for ITN users and 
non-users, and Poisson regression was used to control 
for potential confounding of the association between ITN 
use and mortality, with a random eﬀ ect term used to 
model variation between communities. To estimate the 
number of deaths averted as recommended2,12 we applied 
the rate ratios obtained to the unexposed group.
Role of the funding source 
The funding source had no role in the design, conduct, 
data collection, analysis, or interpretation of this 
study. GWF had full access to all the data. RWS had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Between January, 2005, and December, 2006, there were 
133 deaths in total, with 100 deaths in children aged 
1–59 months identiﬁ ed among a mean cohort of 
3484 children seen over the 2 years of observation. 17 of 
the 33 neonatal deaths occurred in the ﬁ rst year, with 
the remaining 16 in the second year. These neonatal 
deaths were excluded from our analyses. The median 
follow-up time per child was 1·74 (IQR 1·00–1·94) years, 
with a total time at risk for the whole cohort of 6706 years. 
Out-migration rates among the cohort were 9·4% (n=390) 
in the ﬁ rst year and 9·2% (338) in the second year. 
Refusal rates were 0·8% (33) during the ﬁ rst year and 
0·9% (33) in the second year. There were 257 in-migrants; 
193 in year 1 and 64 in year 2. 659 new births were 
identiﬁ ed in the ﬁ rst year and 517 in the second. 
52 deaths occurred before the end of the ﬁ rst year of 
observation (mortality rate 14·5 deaths per 
1000 person-years). By the end of the second year, a 
further 48 deaths had occurred (mortality rate 15·4 deaths 
per 1000 person-years). 87 of the deaths occurred in 
Bondo and Kwale, which are located in areas that 
support high levels of Plasmodium falciparum 
transmission compared with the semi-arid (Makueni) or 
epidemic prone (Kisii) districts.13 
Mortality rates by age, district, calendar year, and ITN 
use are shown in table 1. In the ﬁ rst year, the mortality 
rate in users of ITNs was 13·7 per 1000 person-years of 
follow-up, compared with 14·9 per 1000 person-years in 
non-users, which corresponds to a rate ratio of 0·92 
(95% CI 0·39–2·15). Controlling for district and 
age-group resulted in an adjusted rate ratio of 
0·60 (0·25–1·43). In the second year the mortality rates 
were 11·3 per 1000 person-years in ITN users compared 
with 17·9 per 1000 person-years in non-users, corres-
ponding to a rate ratio of 0·63 (0·34–1·20). Adjustment 
for district and age-group resulted in an adjusted rate 
ratio of 0·57 (0·30–1·09). The combined, adjusted rate 
ratio for the 2 years was 0·58 (0·35–0·98; p=0·04). 
Poisson regression was used to adjust for possible 
confounding factors (table 2). When district was not 
included in the model (model B) there was strong 
evidence of between-cluster variation (p<0·0001). How-
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ever, after inclusion of district in the model (model A) 
there was no evidence of between-cluster variation 
(p=1·0), indicating that although mortality rates vary 
substantially between districts, there is no evidence of 
important between-cluster variation within a district. 
Over the 2-year observation period, after controlling for 
potential confounding factors and using a random 
eﬀ ect to account for the cluster sampling framework, 
ITN use was associated with a 44% reduction in 
mortality (95% CI 4–67; p=0·04; table 2, model B). 
Restricting this analysis to the two more malaria-prone 
areas yielded a rate ratio of 0·50 (0·28–0·90; p=0·02). 
We examined whether the eﬀ ect of ITNs varied between 
districts or from year to year. There was little or no 
evidence of such variation (likelihood ratio χ² 0·16, df 1, 
p=0·69 for district; likelihood ratio χ² 4·15, df 3, p=0·5 
for year). 
If ITN use is indeed associated with a 44% reduction 
in mortality, the scaling-up of ITN coverage could avert 
seven (95% CI 1–11) deaths for every 1000 ITNs used. 
However, there is considerable mortality variation 
by area, ranging from 22 (2–34) averted deaths 
per 1000 ITNs distributed in Bondo to one (0–2) averted 
death per 1000 ITNs distributed in Makueni. 
Discussion
ITN coverage in the four Kenyan districts reported here 
rose from 7% at the end of 2004 to 67% by the end 
of 2006.7 This alone represents a substantial 
improvement in coverage of one of the most eﬃ  cacious 
and cheap evidence-based child survival tools to have 
emerged in recent years.14,15 However, national 
governments and bilateral and multinational agencies 
often cannot deter mine whether increasing 
disease-speciﬁ c intervention coverage contributes to 
improvements in child survival. Here, we have 
assembled data on child mortality and ITN use in an 
eﬀ ort to determine the eﬀ ect of changes in cover age to 
risk of death among children aged 1–59 months. The 
estimated rate of mortality in children reported to have 
used a recently treated bednet was about 56% of that for 
children who did not use an ITN, a protective eﬃ  cacy 
of 44%. Using these estimates of protection, we estimate 
that the scaling-up of ITN coverage might have averted 
about seven deaths for every 1000 ITNs used. However, 
there is considerable mortality variation by area—the 
eﬀ ects were greatest in areas of reported high malaria 
transmission. This ﬁ nding has implications for future 
estimation of possible numbers of deaths averted 
Dec 04–Jan 05 to Dec 05–Jan 06 Dec 05–Jan 06 to Dec 06–Jan 07 Combined follow-up time
Total* With ITN No ITN Total* With ITN No ITN Total* With ITN No ITN
Bondo
1–5 months 8/64·2 (124·6) 1/15·4 (65·0) 7/45·7 (153·2) 4/54·3 (73·7) 2/18·5 (108·1) 2/35·7 (56·0) 12/118·5 (101·3) 3/33·9 (88·48) 9/81·4 (110·6)
6–11 months 9/81·2 (110·8) 3/20·4 (147·4) 6/57·9 (103·6) 8/61·5 (130·0) 2/32·7 (61·2) 6/28·9 (207·6) 17/142·8 (119·0) 5/53·0 (94·3) 12/86·8 (138·2)
1–5 years 13/563·2 (23·1) 0/111·2 (0·0) 13/442·6 (29·4) 16/465·1 (34·4) 6/197·7 (30·4) 10/265·4 (37·7) 29/1028·3 (28·2) 6/308·9 (19·4) 23/708·0 (32· 5)
Rate ratio† 0·50 (0·17–1·47; p=0·20) 0·70 (0·33–1·48; p=0·35) 0·62 (0·33–1·14; p=0·12)
Kisii
1–5 months 1/87·0 (11·5) 0/10·5 (0·0) 1/75·0 (13·3) 2/65·5 (30·5) 2/27·4 (72·9) 0/38·1 (0·0) 3/152·6 (19·7) 2/37·9 (52·8) 1/113·1 (8·8)
6–11 months 0/109·4 (0·0) 0/14·1 (0·0) 0/94·2 (0·0) 0/72·9 (0·0) 0/33·4 (0·0) 0/39·5 (0·0) 0/182·3 (0·0) 0/47·5 (0·0) 0/133·7 (0·0)
1–5 years 5/708·9 (7·1) 1/93·3 (10·7) 4/607·6 (6·6) 1/639·6 (1·6) 0/260·8 (0·0) 1/375·8 (2·7) 6/1348·5 (4·4) 1/354·1 (2·8) 5/983·4 (5·1)
Rate ratio† 1·32 (0·15–11·39; p=0·80) 2·84 (0·25–32·04; p=0·38) 1·91 (0·39–9·30; p=0·42)
Kwale
1–5 months 2/93·8 (21·3) 0/9·1 (0·0) 2/83·0 (24·1) 0/73·2 (0·0) 0/21·5 (0·0) 0/51·6 (0·0) 2/167·0 (12·0) 0/30·6 (0·0) 2/134·6 (14·9)
6–11 months 2/132·2 (15·1) 0/11·6 (0·0) 2/117·8 (17·0) 2/101·0 (19·8) 0/31·1 (0·0) 2/69·0 (29·0) 4/233·2 (17·1) 0/42·7 (0·0) 4/186·8 (21·4)
1–5 years 9/1003·6 (9·0) 0/78·1 (0·0) 9/904·2 (10·0) 14/898·5 (15·6) 1/258·3 (3·9) 13/638·2 (20·4) 23/1902·1(12·1) 1/336·4 (3·0) 22/1542·4 (14·3)
Rate ratio† 0 (0–3·67; p=0·27)‡ 0·16 (0·02–1·23; p=0·04)§ 0·13 (0·02–1·02; p=0·02)§
Makueni
1–5 months 1/66·8 (15·0) 1/7·7 (129·9) 0/58·4 (0·0) 0/47·7 (0·0) 0/20·7 (0·0) 0/27·0 (0·0) 1/114·5 (8·7) 1/28·4 (35·2) 0/85·4 (0·0)
6–11 months 0/87·4 (0·0) 0/11·8 (0·0) 0/74·0 (0·0) 0/59·9 (0·0) 0/26·4 (0·0) 0/33·5 (0·0) 0/147·3 (0·0) 0/38·2 (0·0) 0/107·5 (0·0)
1–5 years 2/595·7 (3·4) 0/55·6 (0·0) 2/521·1 (3·8) 1/572·8 (1·7) 0/218·7 (0·0) 1/350·5 (2·9) 3/1168·4 (2· 6) 0/274·3 (0·0) 3/871·6 (3·4)
Rate ratio† 4·58 (0·38–55·8; p=0·19) 0 (0–60·3; p=0·43)‡ 1·53 (0·21–10·95; p=0·67)
Overall 
1–59 months 52/3593·6 (14·5) 6/438·9 (13·7) 46/3081·7 (14·9) 48/3112·9 (15·4) 13/1147·2 (11·3) 35/1953·2 (17·9) 100/6705·6 (14·9) 19/1586·1 (12·0) 81/5034·9 (16·1)
Rate ratio¶ 0·60 (0·25–1·43; p=0·24) 0·57 (0·30–1·09; p=0·09) 0·58 (0·35–0·98; p=0·04)
Data are deaths/person-years (rate per 1000 person-years) or rate ratio (95% CI; p value). *Person-year totals are larger than the sum of the nets and non-nets person times due to missing data for net status. 
†Mantel-Haenszel adjusted on age-group and also year for combined follow-up time. ‡Not adjusted for age due to lack of data but exact values computed. §Test is approximate, hence discrepancy between 95% 
CI including one and p value being less than 0·05. ¶Adjusted for age-group and district for the yearly surveys and also for year when combined.
Table 1: Deaths, person-years of observation, and mortality rates by period of follow-up, district, and age
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through the combined campaigns between 2003 
and 2006. Clearly, despite high coverage across the 
varied malaria ecologies in Kenya, the numbers of lives 
saved will be greatest in high endemic settings and least 
in areas where transmission is low or very over-
dispersed.
Despite the estimated mortality rate for children who 
used ITN being about half that of those who did not use 
an ITN, the overall mortality rate in the child population 
did not change appreciably over the 2 years of observation. 
One possible explanation for these apparently 
contradictory results is that there was a drought during 
the ﬁ rst year of observation that would have aﬀ ected 
malaria transmission, and that during this period the 
eﬀ ects of wealth status were most marked.7 During the 
second year rainfall was more than twice that recorded 
during the ﬁ rst year and the mass distribution of free 
ITNs, which took place in the second half of the second 
year, removed all inequities in use.7
 Our study design did not seek to measure speciﬁ cally 
the relative contribution of a mass eﬀ ect on local vector 
population survival or disease risks. However, our results 
did not show evidence of a mass eﬀ ect over and above 
that of individual protection when adjusted for quartiles 
of community enumerated net coverage (table 2). Another 
possible confounding eﬀ ect could have been the 
introduction of new antimalarial drugs, especially the 
arthemether-containing treatments that are known to 
have anti-gametocyte activity and hence have the potential 
to reduce malaria transmission. Arthemether-lume-
fantrine was starting to be deployed in government 
clinics between July and September, 2006, with 
nationwide coverage achieved during the last quarter 
of 2006. We have done a cross-sectional survey in the 
same four districts as described here in August, 2006. 
During this survey the proportion of children reporting a 
fever in the last 14 days who were treated with 
arthemether-lumefantrine was 1·3% (unpublished data), 
and the proportion reporting being treated within 
48 hours with arthemether-lumefantrine was only 0·6%. 
Neither indicator suggests that changing access to 
eﬀ ective arthemether-containing medicines would have 
greatly aﬀ ected the mortality eﬀ ects reported here.
The size of eﬀ ect is particularly striking because it is 
greater than the pooled estimate of protection under 
conditions of eﬃ  cacy trials.1 We attempted to control for 
several important covariates associated with child 
survival, but there will be covariates we have not included 
and our deﬁ nition of exposure might have an element of 
bias. Unlike carefully controlled trials, and given the 
ethical constraints of repeated investigations of cohorts 
of children not sleeping under nets, we cannot be 
completely certain about the reported use of the ITNs by 
children who died. A further possible source of bias is 
that some of those who had either out-migrated or were 
age-censored by reaching age 5 between the midpoint 
survey and the last cross-sectional survey could have been 
deaths. However, among this subset of children the 
proportion of ITN users at the time of the midpoint 
survey was the same as the overall population and any 
bias that such missed deaths could have introduced is 
likely to be non-diﬀ erential. Further, given the advanced 
age of these children, the probability of death among 
such children has to be fairly small (table 2). 
The national estimate of protection aﬀ orded through 
the expansion of the Kenyan ITN delivery programme 
might be more conservative than we have shown in 
districts that were able to achieve over 67% coverage. We 
are nevertheless conﬁ dent that a substantial eﬀ ect on 
child survival was achieved during the expansion phase 
of the ITN strategy and might have reduced by over a 
third the numbers of childhood deaths in high coverage 
districts in 2006. Donor agencies should regard this as 
money well spent and recognise that the challenge is 
now to maintain and increase funding to expand coverage 
further.
Model A Model B
Use ITN 0·51 (0·30–0·87; p=0·01) 0·56 (0·33–0·96; p=0·04)
District†
Kisii 0·12 (0·06–0·24; p<0·0001) ..
Kwale 0·26 (0·16–0·41; p<0·0001) ..
Makueni 0·06 (0·02–0·17; p<0·0001) ..
Year (2005 vs 2006) 0·75 (0·50–1·13; p=0·17) 0·75 (0·50–1·13; p=0·18)
Sex (female) 0·68 (0·45–1·02; p=0·06) 0·66 (0·44–0·99; p=0·05)
Child’s age‡
6–11 months 0·96 (0·51–1·81; p=0·90) 0·94 (0·50–1·77; p=0·85)
1–2 years 0·87 (0·49–1·52; p=0·62) 0·84 (0·48–1·47; p=0·54)
2–3 years 0·28 (0·14–0·58; p=0·001) 0·28 (0·14–0·57; p=0·0003)
3–4 years 0·14 (0·06–0·35; p<0·0001) 0·14 (0·05–0·35; p<0·0001) 
4–5 years 0·09 (0·03–0·30; p<0·0001) 0·09 (0·03–0·30; p<0·0001)
Mother had some education§ 0·87 (0·44–1·72; p=0·73) 1·11 (0·61–2·03; p=0·73)
Mother >30 years old 0·88 (0·56–1·37; p=0·58) 0·83 (0·53–1·29; p=0·41)
Wealth quintile¶
Second 1·11 (0·60–2·04; p=0·75) 1·12 (0·60–2·10; p=0·73)
Third 1·30 (0·72–2·34; p=0·39) 1·34 (0·72–2·54; p=0·34) 
Fourth 1·18 (0·63–2·22; p=0·61) 1·30 (0·66–2·55; p=0·45)
Fifth 1·23 (063–2·37; p=0·55) 1·44 (0·71–2·94; p=0·31)
Tertile of distance to health facility||
Middle 1·17 (0·69–1·98; p=0·57) 1·07 (0·59–1·94; p=0·83)
Furthest 1·08 (0·63–1·86; p=0·78) 1·01 (0·52–1·96; p=0·97)
Quartiles of net coverage of each enumeration area**
Second 1·01 (0·59–1·72; p=0·98) 1·25 (0·57–2·72; p=0·58)
Third 0·55 (0·28–1·01; p=0·08) 0·58 (0·24–1·41; p=0·23)
Fourth 1·32 (0·73–2·37; p=0·36) 1·11 (0·49–2·54; p=0·80)
Data are rate ratio (95% CI; p value). *Cluster (ie, community) level random eﬀ ects parameter (θ) in model A was 0·00 
(95% CI 0–0; p=1·0), and in model B was 0·67 (95% CI 0·29–1·53; p<0·0001). †Reference group is Bondo. ‡Reference 
group is 1–5 month olds. §Taken from models with 97 rather than 100 deaths due to missing values of maternal 
education; all other parameter values remained essentially unchanged. ¶ Reference group is most poor—ie, ﬁ rst wealth 
quintile. ||Middle corresponds to a range of about 30 min to 1 h. Furthest corresponds to about 1–5 h. **Second ranges 
from 23% to 30%, third ranges from 30% to 35%, fourth from 35% to 62%. 
Table 2: Adjusted mortality rate ratios*
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